Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2021 | 12-2020 | 09-2020 | 06-2020 | 03-2020 | |
| Sales | 52,304 | 56,036 | 59,988 | 90,142 | 88,478 |
| Cost of Goods | 34,606 | 80,111 | 24,239 | 59,089 | 18,613 |
| Gross Profit | 17,698 | -24,075 | 35,749 | 31,053 | 69,865 |
| Operating Expenses | 83,240 | 62,823 | 94,083 | 204,961 | 129,603 |
| Operating Income | -64,936 | -86,787 | -58,095 | -173,819 | -59,125 |
| Interest Expense | 4,805 | 2,317 | 2,274 | 2,308 | 1,972 |
| Other Income | 161 | 720 | 410 | 376 | 350 |
| Pre-tax Income | -69,580 | -88,384 | -59,959 | -175,751 | -60,747 |
| Net Income Continuous | -69,580 | -88,384 | -59,959 | -175,751 | -60,747 |
| Net Income | $-69,580 | $-88,384 | $-59,959 | $-175,751 | $-60,747 |
| EPS Basic Total Ops | -0.45 | -0.61 | -0.42 | -1.28 | -0.47 |
| EPS Basic Continuous Ops | -0.45 | -0.60 | -0.42 | -1.28 | -0.47 |
| EPS Diluted Total Ops | -0.45 | -0.61 | -0.42 | -1.28 | -0.47 |
| EPS Diluted Continuous Ops | -0.45 | -0.60 | -0.42 | -1.28 | -0.47 |
| EBITDA(a) | $-55,423 | $-79,079 | $-51,504 | $-48,673 | $-49,500 |